NEW YORK, March 1 (GenomeWeb News) - Strategic Diagnostics said today that it will offer a new high-throughput antibody reagent production service for customers in the proteomics, pharmaceutical, diagnostics, and biomedical research industries.
The technology, based on a process called genetic immunization, will allow Strategic Diagnostics to manufacture custom antibodies in high throughput based on specific genetic sequences provided by the customer, the company said.
Strategic Diagnostics, which is based in Newark, Del., also said that it has opened a research facility in Dallas dedicated to the new service, and has hired two new scientists to oversee the initiative: Ross Chambers and David Fancy, who join the company from the University of Texas, Southwestern Medical Center. Chambers and Fancy are widely recognized for their work in genetic immunization, Strategic Diagnostics said.